Trial site
Hospital Universitari de Santa Maria
Lleida, Lleida [Lérida] 25198, SpainNot linked to an institution yet
- 18running trials
- 5closed trials
The trials here
What the 24 trials at this site are about, from their registry records.
- Phase
- Phase 316 trials
- Phase 26 trials
- Phase 42 trials
- Status
- Recruiting9 trials
- Active, not recruiting5 trials
- Not yet recruiting4 trials
- Completed3 trials
- Terminated2 trials
- Suspended1 trial
- Lead sponsor
- Biogen3 trials
- Bristol-Myers Squibb2 trials
- Eli Lilly and Company2 trials
- Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre2 trials
- LETI Pharma S.L.U.2 trials
- and 12 more
Running trials
Not yet recruiting
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER‑OSA 1)
2026-526327-22-00· Phase 3· Pfizer Inc.· Source
Not yet recruiting
A study to learn about the effects of Trontinemab in participants at risk for Alzheimer‘s disease
2025-524314-29-00· Phase 3· F. Hoffmann-La Roche AG· Source
Not yet recruiting
ObStructive Sleep Apnoea ManageMent in Older AdUlts with Overweight or ObEsity: A Randomized ClinicaL Trial (SAMUEL study)
2026-525500-10-00· Phase 4· Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre· Source
Recruiting
Grass/Olive Immunotherapy for Rhinitis and Asthma (GOES)
2025-521709-42-00· Phase 3· LETI Pharma S.L.U.· Source
Recruiting
Grass Immunotherapy for Rhinitis and Asthma (GIRA)
2025-521736-10-00· Phase 3· LETI Pharma S.L.U.· Source
Recruiting
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
NCT07571109· Phase 3· Novo Nordisk A/S· Source
Recruiting
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
NCT07571005· Phase 3· Novo Nordisk A/S· Source
Not yet recruiting
TheRapeutic StrAtegies for Obstructive SleeP Apnea in Older Adults with OverweigHt or Obesity: A RandomizEd Clinical TriaL (RAPHAEL study)
2025-524819-37-00· Phase 4· Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre· Source
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT07369011· Phase 3· Eli Lilly and Company· Source
Contact: Ferran Barbé Illa (principal investigator)
Recruiting
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
NCT07177339· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216· Phase 3· Bristol-Myers Squibb· Source
Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Recruiting
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
NCT06559150· Phase 2· Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA· Source
Active, not recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
NCT06268886· Phase 2· Bristol-Myers Squibb· Source
Active, not recruiting
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
NCT05399888· Phase 2· Biogen· Source
Recruiting
Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen
NCT04891237· Phase 3· Inmunotek S.L.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Terminated
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
NCT05310071· Phase 3· Biogen· Source
Completed
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
NCT05318976· Phase 2· Inmune Bio, Inc.· Source
Completed
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease
2022-501188-42-00· Phase 2· Janssen - Cilag International· Source
Terminated
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
NCT04241068· Phase 3· Biogen· Source
Completed
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
NCT03393520· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source
Report an error